Don't Let Distribution Derail Your CGT Launch

Crafting a robust commercial distribution strategy is crucial for the success of a cell and gene therapy (CGT) launch. Given the unique logistical complexities of these therapies—including ultra-low temperature storage and strict chain of identity requirements—anticipating and addressing distribution challenges before launch is essential to ensure a seamless transition from clinical trials to patient access.

To optimize CGT distribution, manufacturers should focus on four key areas : developing an effective channel strategy to optimize patient access , proactively integrating new sites of care as the market grows , establishing critical support systems for sites of care , and building strategic flexibility into the plan to adapt to changing stakeholder needs. These recommended strategies can help drug manufacturers overcome common challenges as they move into commercial distribution. To learn how to overcome these distribution challenges, read the full article.